Patents by Inventor Jonathan L. Sessler
Jonathan L. Sessler has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 5801229Abstract: Texaphyrins are provided for use as radiation sensitizers. Advantageous properties of texaphyrins for use as a radiation sensitizer include: i) a low redox potential which allows radiation-induced hydrated electrons to flow to texaphyrin rather than neutralizing hydroxyl radicals, allowing hydroxyl radicals to cause cellular damage, ii) a relatively stable texaphyrin radical that reacts readily to covalently modify neighboring molecules causing further cellular damage, iii) intrinsic biolocalization, and iv) indifference to the presence or absence of O.sub.2. These properties allow texaphyrins to be particularly effective for treating the hypoxic areas of solid neoplasms. Methods of treatment for an individual having a neoplasm or atheroma include the use of a texaphyrin as a radiation sensitizer and as an agent for photodynamic tumor therapy, or the use of a texaphyrin for internal and for external ionizing radiation. Novel texaphyrins are provided.Type: GrantFiled: September 13, 1996Date of Patent: September 1, 1998Assignee: The Board of Regents, University of Texas SystemInventors: Jonathan L. Sessler, Tarak D. Mody, Gregory W. Hemmi, Vladimir A. Kral
-
Patent number: 5798491Abstract: The invention is directed to a particular class of metal complexes, specifically certain texaphyrin metal complexes, which both hydrolyze and photocleave RNA, and which also both hydrolyze RNA and photocleave DNA.In one embodiment, the present invention is directed to a method for both hydrolyzing and photocleaving a polymer of ribonucleic acid, the method comprising the steps of contacting the polymer of ribonucleic acid with a texaphyrin metal complex exhibiting catalytic activity for both hydrolysis and photocleavage of ribonucleic acid polymers, incubating the polymer and the metal complex under conditions and for a time sufficient to hydrolyze the phosphate ester bond of the polymer, and exposing the texaphyrin metal complex to light for a time sufficient to photocleave the polymer.Type: GrantFiled: June 2, 1995Date of Patent: August 25, 1998Assignees: Board of Regents, The University of Texas System, Pharmacyclics, Inc.Inventors: Darren Magda, Jonathan L. Sessler
-
Patent number: 5763172Abstract: A method of phosphate ester hydrolysis including incubating a solution of an aqueous phosphate ester with a metallotexaphyrin complex under conditions and for a time sufficient to hydrolyze the phosphate ester. The metal is a metal cation having catalytic activity for ester bond hydrolysis in aqueous solution. Phosphate ester substrates include nucleic acid such as RNA, phosphoric anhydrides, phospholipids, and alkyl phosphate esters.Type: GrantFiled: June 7, 1995Date of Patent: June 9, 1998Assignees: Board of Regents, The University of Texas System, Pharmacyclics, Inc.Inventors: Darren Magda, Jonathan L. Sessler, Meredith Wright, Richard A. Miller, William C. Dow
-
Patent number: 5756726Abstract: Novel texaphyrin compounds having improved functionalization are described. Metal complexes of these compounds are active as photosensitizers for the generation of singlet oxygen and thus are potentially useful for treatments performed with singlet oxygen. Several of the metallotexaphyrin complexes absorb light in the physiologically important range of 690-880 nm. The complexes form long-lived triplet states and thus may act as efficient photosensitizers for generation of singlet oxygen.Type: GrantFiled: June 6, 1995Date of Patent: May 26, 1998Assignees: Pharmacyclics, Inc., Board of Regents, The University of Texas SystemInventors: Gregory W. Hemmi, Jonathan L. Sessler, Tarak D. Mody
-
Patent number: 5744302Abstract: The present invention provides various novel covalently modified sapphyrin derivatives and conjugates; polymers including sapphyrin or derivatives thereof; and chromatographic supports including sapphyrins and other expanded porphyrins and derivatives thereof. Disclosed are water soluble sapphyrins, including polyhydroxysapphyrins and sapphyrin-sugar derivatives; sapphyrin-metal chelating conjugates; sapphyrin nucleobase conjugates; oligosapphyrins and polysapphyrins, including sapphyrin dimers, trimers, oligomers and higher polymers; and polymer supported expanded porphyrin compositions, including advantageous rubyrin- and sapphyrin-based chromatography columns and electrophoretic supports. Sapphyrin oligomers and polymers and polymer supported expanded porphyrins, such as, e.g.Type: GrantFiled: May 11, 1995Date of Patent: April 28, 1998Assignee: Board of Regents, The University of Texas SystemInventors: Jonathan L. Sessler, Brent L. Iverson, Vladimir Kral, Kevin Shreder, Hiroyuki Furuta, Richard E. Thomas
-
Patent number: 5733903Abstract: The present invention relates to the use of water-soluble texaphyrin-diamagnetic metal complexes retaining lipophilicity as photosensitizers in the treatment of benign and malignant neoplastic tissue.Type: GrantFiled: July 10, 1996Date of Patent: March 31, 1998Assignee: Board of Regents, The University of Texas SystemInventors: Jonathan L. Sessler, Gregory W. Hemmi, Tarak D. Mody
-
Patent number: 5714328Abstract: Methods for photocleavage of a polymer of ribonucleic acid using a texaphyrin or a texaphyrin metal complex are provided. A preferred method of use is the site-specific cleavage of a polymer of ribonucleic acid and a preferred texaphyrin is a derivatized texaphyrin having binding specificity, in particular, a texaphyrin covalently coupled to a site-directing molecule, preferably an oligonucleotide. Possible substrates for cleavage include messenger, ribosomal, transfer, small nuclear, and small cytosolic ribonucleic acids, and RNA cofactors, thereby inactivating these ribonucleic acids and providing a multifaceted approach for treating benign or malignant cancer cells, or other undesired cells or tissues.Type: GrantFiled: June 7, 1995Date of Patent: February 3, 1998Assignees: Board of Regents, the University of Texas System, Pharmacyclics, Inc.Inventors: Darren Magda, Jonathan L. Sessler
-
Patent number: 5672490Abstract: The present invention provides various novel covalently modified sapphyrin derivatives and conjugates; polymers including sapphyrin or derivatives thereof; and chromatographic supports including sapphyrins and other expanded porphyrins and derivatives thereof. Disclosed are water soluble sapphyrins, including polyhydroxysapphyrins and sapphyrin-sugar derivatives; sapphyrin-metal chelating conjugates; sapphyrin nucleobase conjugates; oligosapphyrins and polysapphyrins, including sapphyrin dimers, trimers, oligomers and higher polymers; and polymer supported expanded porphyrin compositions, including advantageous rubyrin- and sapphyrin-based chromatography columns and electrophoretic supports. Sapphyrin oligomers and polymers and polymer supported expanded porphyrins, such as, e.g.Type: GrantFiled: June 2, 1995Date of Patent: September 30, 1997Assignee: The University of Texas Board of RegentsInventors: Jonathan L. Sessler, Brent L. Iverson, Vladimir Kral, Kevin Shreder, Hiroyuki Furuta, Richard E. Thomas
-
Patent number: 5633354Abstract: The invention is directed to a method of incorporating expanded porphyrins, and particularly of incorporating a sapphyrin or a texaphyrin, before, during, or after chemical synthesis of an oligomer to form an expanded porphyrin-oligonucleotide conjugate, and particularly a sapphyrin- or texaphyrin-oligonucleotide conjugate. This method includes reacting derivatized nucleotides and a sapphyrin or a texaphyrin in a desired order in an automated or manual DNA synthesizer having a solid support to form a sapphyrin- or a texaphyrin-oligonucleotide conjugate.Type: GrantFiled: March 13, 1996Date of Patent: May 27, 1997Assignees: Pharmacyclics, Inc., Board of Regents, The University of TexasInventors: Darren Magda, Jonathan L. Sessler, Brent L. Iverson, Petra I. Sansom, Shaun P. Crofts
-
Patent number: 5632970Abstract: Texaphyrins are provided for use as radiation sensitizers. Advantageous properties of texaphyrins for use as a radiation sensitizer include: i) a low redox potential which allows radiation-induced hydrated electrons to flow to texaphyrin rather than neutralizing hydroxyl radicals, allowing hydroxyl radicals to cause cellular damage, ii) a relatively stable texaphyrin radical that reacts readily to covalently modify neighboring molecules causing further cellular damage, iii) intrinsic biolocatization, and iv) indifference to the presence or absence of O.sub.2. These properties allow texaphyrins to be particularly effective for treating the hypoxic areas of solid neoplasms. Methods of treatment for an individual having a neoplasm or atheroma include the use of a texaphyrin as a radiation sensitizer and as an agent for photodynamic tumor therapy, or the use of a texaphyrin for internal and for external ionizing radiation. Novel texaphyrins are provided.Type: GrantFiled: June 7, 1995Date of Patent: May 27, 1997Assignees: Board of Regents, The University of Texas, Pharmacyclics, Inc.Inventors: Jonathan L. Sessler, Tarak D. Mody, Gregory W. Hemmi, Vladimir A. Kr al, Darren Magda
-
Patent number: 5622945Abstract: The present invention is directed to the synthesis and use of novel macrocyclic compounds, based upon a new class of expanded porphyrins, termed rubyrins. Disclosed herein is the structure and synthesis of a prototypical rubyrin and various substituted rubyrin analogues, conjugates and compositions. Rubyrin itself is characterized by the presence of six pyrrolic subunits contained within a fully aromatic 26 .pi.-electron macrocyclic framework and by UV/VIS absorption bands that are very red-shifted as compared to those of other porphyrins or pentapyrrolic expanded porphyrins. The rubyrin-type class of compounds is further characterized by an ability to undergo facile protonation at the pyrrolic nitrogens and, once protonated, by an ability to form complexes with anions such as nucleotide-containing compounds. Rubyrin-based compounds are useful as, for example, anion chelators and receptors and as transporters for various anionic compounds including antiviral agents. In addition to the 26 .pi.Type: GrantFiled: January 4, 1995Date of Patent: April 22, 1997Assignee: Board of Regents, The University of Texas SystemInventors: Jonathan L. Sessler, Takashi Morishima, Steven J. Weghorn
-
Patent number: 5622946Abstract: Texaphyrins are provided for use as radiation sensitizers. Advantageous properties of texaphyrins for use as a radiation sensitizer include: i) a low redox potential which allows radiation-induced hydrated electrons to flow to texaphyrin rather than neutralizing hydroxyl radicals, allowing hydroxyl radicals to cause cellular damage, ii) a relatively stable texaphyrin radical that reacts readily to covalently modify neighboring molecules causing further cellular damage, iii) intrinsic biolocalization, and iv) indifference to the presence or absence of O.sub.2. These properties allow texaphyrins to be particularly effective for treating the hypoxic areas of solid neoplasms. Methods of treatment for an individual having a neoplasm or atheroma include the use of a texaphyrin as a radiation sensitizer and as an agent for photodynamic tumor therapy, or the use of a texaphyrin for internal and for external ionizing radiation. Novel texaphyrins are provided.Type: GrantFiled: May 10, 1995Date of Patent: April 22, 1997Assignees: Pharmacyclics, Inc., Board of Regents, Univ. of Tex. Sys.Inventors: Jonathan L. Sessler, Anthony M. Harriman, Richard A. Miller
-
Patent number: 5607924Abstract: Methods of cleavage of a polymer of deoxyribonucleic acid using photosensitive texaphyrins are disclosed. A preferred method of use is the site-specific cleavage of a polymer of deoxyribonucleic acid and a preferred texaphyrin is a derivatized texaphyrin having binding specificity, in particular, a texaphyrin covalently coupled to a site-directing molecule, preferably an oligonucleotide.Type: GrantFiled: June 6, 1995Date of Patent: March 4, 1997Assignees: Pharmacyclics, Inc., Board of Trustees, Univ. of TX Sys.Inventors: Darren Magda, Jonathan L. Sessler, Brent L. Iverson, Petra I. Sansom, Meredith Wright
-
Patent number: 5601802Abstract: Texaphyrin metal complexes having improved functionalization include the addition of electron-donating groups to positions 2, 7, 12, 15, 18 and/or 21 and/or the addition of electron-withdrawing groups to positions 15 and/or 18 of the macrocycle. Electron-donating groups at positions 2, 7, 12, 15, 18 and/or 21 contribute electrons to the aromatic .pi. system of the macrocycle which stabilizes the metal complex to demetallation and the imine bonds to hydrolysis. These texaphyrin metal complexes having enhanced stability are useful for localization, magnetic resonance imaging, radiosensitization, radiation therapy, fluorescence imaging, photodynamic therapy, RNA hydrolysis, DNA photocleavage, and applications requiring singlet oxygen production for cytotoxicity. Electron-withdrawing groups at positions 15 and/or 18 render the macrocycle more readily reduced, i.e. the redox potential is lower and the macrocycle more readily gains an electron to form a radical.Type: GrantFiled: June 7, 1995Date of Patent: February 11, 1997Assignees: Pharmacyclics, Inc., Board of Trustees, Univ. of TX Sys.Inventors: Gregory W. Hemmi, Jonathan L. Sessler, Tarak D. Mody
-
Patent number: 5599928Abstract: Texaphyrin metal complexes having improved functionalization include the addition of electron-donating groups to positions 2, 7, 12, 15, 18 and/or 21 and/or the addition of electron-withdrawing groups to positions 15 and/or 18 of the macrocycle. Electron-donating groups at positions 2, 7, 12, 15, 18 and/or 21 contribute electrons to the aromatic .pi. system of the macrocycle which stabilizes the metal complex to demetallation and the imine bonds to hydrolysis. The addition of substituents to the 12 and 21 positions of the macrocycle offer steric protection for the imine bonds against possible in vivo enzyme hydrolysis. Electron-withdrawing groups at positions 15 and/or 18 render the macrocycle more readily reduced, i.e. the redox potential is lower and the macrocycle more readily gains an electron to form a radical. Such texaphyrins having a low redox potential and imine bond stabilization are useful in a variety of applications.Type: GrantFiled: June 2, 1995Date of Patent: February 4, 1997Assignees: Pharmacyclics, Inc., Board of Regents, The University of Texas SystemInventors: Gregory W. Hemmi, Jonathan L. Sessler, Tarak D. Mody
-
Patent number: 5599923Abstract: Texaphyrin metal complexes having improved functionalization including the addition of electron donating groups to positions 12, 15, 18 and/or 21 and/or the addition of electron withdrawing groups to positions 15 or 18 of the macrocycle. Electron donating groups at positions 12, 15, 18 and/or 21 contribute electrons to the aromatic .pi. system of the macrocycle which stabilizes the metal complex to demetallation and the imine bonds to hydrolysis, these texaphyrin metal complexes having enhanced stability are useful for localization, magnetic resonance imaging, radiosensitization, radiation therapy, fluorescence imaging, photodynamic tumor therapy and applications requiring singlet oxygen production for cytotoxicity. Electron withdrawing groups at positions 15 or 18 render the macrocycle more readily reduced, i.e. the redox potential is lower and the macrocycle more readily gains an electron to form a radical. Such texaphyrins having a low redox potential are useful for radiosensitization applications.Type: GrantFiled: February 15, 1994Date of Patent: February 4, 1997Assignees: Board of Regents, University of TX, Pharmacyclics, Inc.Inventors: Jonathan L. Sessler, Tarak D. Mody, Gregory W. Hemmi
-
Patent number: 5595726Abstract: The present invention is directed to chromophoric probes for use in detecting nucleic acid sequences. More particularly, the invention is directed to probes that comprise a texaphyrin chromophore molecule covalently coupled or conjugated to a site-directing molecule, the site-directing molecule having affinity for a biological receptor or a nucleic acid sequence. In one embodiment of the invention, the probe comprises a texaphyrin chromophore conjugated to an oligonucleotide having complementary binding affinity for a target nucleic acid sequence.Type: GrantFiled: June 7, 1995Date of Patent: January 21, 1997Assignees: Pharmacyclics, Inc., Board of Trustees, Univ. of TX Sys.Inventors: Darren Magda, Jonathan L. Sessler, Brent Iverson
-
Patent number: 5594136Abstract: The present invention provides various novel matrix-supported texaphyrins in which a polymeric or solid matrix is covalently modified by the addition of one or more texaphyrins or texaphyrin derivatives. Described are methods of making various polymer-supported texaphyrins, including texaphyrin chromatographic supports, and devices such as catheters, as may be used, for example, in the separation of neutral and anionic species and in applications concerning phosphate ester hydrolysis, other catalytic schemes, MRI, and PDT.Type: GrantFiled: May 3, 1995Date of Patent: January 14, 1997Assignees: Pharmacyclics, Inc., Board of Regents, The University of TexasInventors: Jonathan L. Sessler, Brent L. Iverson, Vladimir Kr al, Richard E. Thomas, Darren Magda, Daniel A. Smith
-
Patent number: 5591422Abstract: Texaphyrin metal complexes having improved functionalization include the addition of electron-donating groups to positions 2, 7, 12, 15, 18 and/or 21 and/or the addition of electron-withdrawing groups to positions 15 and/or 18 of the macrocycle. Electron-donating groups at positions 2, 7, 12, 15, 18 and/or 21 contribute electrons to the aromatic .pi. system of the macrocycle which stabilizes the metal complex to demetallation and the imine bonds to hydrolysis. These texaphyrin metal complexes having enhanced stability are useful for localization, radiosensitization and radiation therapy. Electron-withdrawing groups at positions 15 and/or 18 render the macrocycle more readily reduced, i.e. the redox potential is lower and the macrocycle more readily gains an electron to form a radical. Such texaphyrins having a low redox potential are useful for radiation sensitization applications.Type: GrantFiled: June 6, 1995Date of Patent: January 7, 1997Assignees: Pharmacyclics, Inc., Board of Regents, The University of Texas SystemInventors: Gregory W. Hemmi, Jonathan L. Sessler, Tarak D. Mody
-
Patent number: 5587463Abstract: The present invention involves a novel tripyrrole dimethine-derived "expanded porphyrin" (texaphyrin), the synthesis of such compounds, their analogs or derivatives and their uses. These expanded porphyrin-like macrocycles are efficient chelators of divalent and trivalent metal ions. Metal complexes of these compounds are active as photosensitizers for the generation of singlet oxygen and thus potentially for inactivation or destruction of human immunodeficiency virus (HIV-1), mononuclear or other cells infected with such virus and tumor cells as well. A variety of texaphyrin derivatives have been produced and many more are readily obtainable. Various metal (e.g., transition, main group, and lanthanide) complexes with the texaphyrin and texaphyrin derivatives of the present invention have unusual water solubility and stability which render them particularly useful. These metallotexaphyrin complexes have optical properties making them unique as compared to existing porphyrin-like or other macrocycles.Type: GrantFiled: March 8, 1994Date of Patent: December 24, 1996Assignee: Board of Regents, The University of Texas SystemInventors: Jonathan L. Sessler, Gregory W. Hemmi, Toshiaki Murai